A new analysis shows how Bruton tyrosine kinase (BTK) inhibitors affect full-length BTK conformation by investigating the ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...

Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s ...

At the 66th American Society of Hematology Annual Meeting, a plethora of companies presented clinical trial data highlighting ...

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of ...

Innovent Biologics and Lilly expand collaboration agreement to commercialize BTK inhibitor, Jaypirca in Mainland China: San Francisco Tuesday, December 17, 2024, 11:00 Hrs [IST] I ...

covalent Bruton’s tyrosine kinase (BTK) inhibitor, and further support its potential as a first-in-class treatment for ITP. Platelet response was achieved in 65% (n=86) of patients receiving ...

In October 2024, Jaypirca ® (pirtobrutinib) received approval from China's National Medical Products Administration (NMPA) as monotherapy for the treatment of adult patients with relapsed or ...

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...

In the pivotal LUNA 3 study, adult patients with persistent or chronic ITP and severely low platelet counts (median of 15,000/μL) received oral rilzabrutinib 400 mg twice a day (n=133) or placebo ...

Tyrosine kinase inhibitors (TKIs) are a class of targeted cancer therapies designed to block the action of tyrosine kinases, enzymes that play a key role in cellular functions such as growth, division ...